Striving to Make O-15 Water Clinically Available
MedTrace Pharma is a development stage radiopharmaceutical and device company with headquarters in Minneapolis, MN and Horsholm, Denmark.
We are committed to developing innovative technology to make O-15 water practically available for routine cardiac diagnostic PET imaging.
Our O-15 water and automated manufacturing technology is being investigated under the FDA approved IND #135360 and in the Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered [15-O]-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW) NCT05134012. Researchers interested in this study or other novel applications can contact Emily Vandenbroucke, PhD at emily@medtrace.dk to schedule an appointment or stop by our booth.
Please visit MedTrace Pharma Booth #2030 to learn more about our technology and potential collaboration opportunities.
Brands: MedTrace Pharma, [15-O]-H2O injection, O-15 Water, O-15 H2O for diagnostic PET imaging, [O-15]-Water PET Myocardial Perfusion Imaging (MPI), novel PET imaging agent labeled with the radioisotope [15-O], aQuant quantitative imaging software, P3 System (MT-100)